WeSearch

Experimental Drug Yields Dramatic Weight Loss

4 sources covered this compare →
Coverage among the outlets varies in emphasis. The New York Times highlights the dramatic nature of the weight loss, framing it as a breakthrough in obesity treatment. NBC News focuses on the comparative effectiveness of the drug to…
https://www.nytimes.com/by/gina-kolata· ·3 min read · 0 reactions · 0 comments · 36 views
Experimental Drug Yields Dramatic Weight Loss
TL;DR · WeSearch summary

Eli Lilly reported that participants receiving the experimental drug retatrutide lost an average of 28 percent of their body weight after 80 weeks. The results were presented in a study published by the New York Times on May 21, 2026. The findings suggest the drug could become a significant option for obesity treatment pending further regulatory review.

Key facts
How this story was covered

4 outlets in our directory ran this story, first to last over 33 hours. Coverage spans 3 points on the political spectrum — 1 lean left, 1 centre, 1 lean right.

Lean left · 1Centre · 1Lean right · 1
About this source

NYT — Home files mainly under news. We currently carry 1,556 of its stories.

Original article
NYT > Top Stories · https://www.nytimes.com/by/gina-kolata
Read full at NYT > Top Stories →

Story provenance

Source · retrieval · rights · ranking — open for full record
inspect →

Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.

Record

Original publisherNYT > Top Stories
Canonical URLhttps://www.nytimes.com/2026/05/21/science/retatrutide-weight-loss-drug.html
Publication timeThu, 21 May 2026 10:45:05 +0000
Retrieval time2026-05-21T10:51:10.728Z
Last seen2026-05-21T11:03:17.016Z
Headline sourcePublisher (no WeSearch rewrite)
Excerpt sourcepublisher body
Excerpt methodFirst ~120 words (~800 chars) of extracted publisher body, fair-use limited.
SummaryWeSearch · cerebras-chat (WeSearch summarizer)
Summary source textcontentText
Citation coverageSummary is a WeSearch-generated derivative; primary citation is the original publisher URL.
Cluster7hq_qh4jc-OV · 4 stories
Cluster logicGrouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison.
Ranking reasonStory pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking.
Publisher visitYes — open original
Substitutes article?No — link-out required for full text

Rights status (four layers)

Publisher-declared
No publisher-confirmed rights record for this source yet.
Machine-readable
No source-specific machine-readable restriction detected beyond the public feed.
WeSearch interpretation
WeSearch declared handling (basis: Derived from the published RSS/Atom feed). This is WeSearch policy, not a legal grant on the publisher's behalf.
Unknown
Retrieval and training permissions are not asserted unless the publisher confirms them.

WeSearch handling by dimension

Indexing May the item be indexed (stored, ranked, made findable)? Allowed
Snippet May a short excerpt of the publisher's text be shown? Allowed
AI summary May WeSearch generate its own short summary of the article? Limited
Retrieval / RAG May the content be exposed for third-party retrieval-augmented generation? Not asserted
Model training May the content be used to train AI models? Not asserted
Commercial reuse May the content be reused commercially? Not permitted

Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.

Opening excerpt (first ~120 words) tap to expand

AdvertisementSKIP ADVERTISEMENTYou have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load.Supported bySKIP ADVERTISEMENTExperimental Drug Yields Dramatic Weight LossPeople who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.Listen · 7:01 min Share full article569Eli Lilly’s headquarters in Indianapolis.Credit...AJ Mast/BloombergBy Gina Kolata and Rebecca RobbinsPublished May 21, 2026Updated May 22, 2026Leer en español !function(){var e="gps_module_impressions",s="gps_suppress_module",t=new URLSearchParams(window.location.search),o="1"===t.get("gps_debug")?function(e,s){console.log("[gps]",e,void…

Excerpt limited to ~120 words for fair-use compliance. The full article is at NYT > Top Stories.

Anonymous · no account needed
Share 𝕏 Facebook Reddit LinkedIn Threads WhatsApp Bluesky Mastodon Email

Discussion

0 comments

More from NYT > Top Stories